Literature DB >> 9294114

Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor.

R W Colman1, R A Pixley, S Najamunnisa, W Yan, J Wang, A Mazar, K R McCrae.   

Abstract

The urokinase receptor (uPAR) binds urokinase-type plasminogen activator (u-PA) through specific interactions with uPAR domain 1, and vitronectin through interactions with a site within uPAR domains 2 and 3. These interactions promote the expression of cell surface plasminogen activator activity and cellular adhesion to vitronectin, respectively. High molecular weight kininogen (HK) also stimulates the expression of cell surface plasminogen activator activity through its ability to serve as an acquired receptor for prekallikrein, which, after its activation, may directly activate prourokinase. Here, we report that binding of the cleaved form of HK (HKa) to human umbilical vein endothelial cells (HUVEC) is mediated through zinc-dependent interactions with uPAR. These occur through a site within uPAR domains 2 and 3, since the binding of 125I-HKa to HUVEC is inhibited by vitronectin, anti-uPAR domain 2 and 3 antibodies and soluble, recombinant uPAR (suPAR), but not by antibody 7E3, which recognizes the beta chain of the endothelial cell vitronectin receptor (integrin alphavbeta3), or fibrinogen, another alphavbeta3 ligand. We also demonstrate the formation of a zinc-dependent complex between suPAR and HKa. Interactions of HKa with endothelial cell uPAR may underlie its ability to promote kallikrein-dependent cell surface plasmin generation, and also explain, in part, its antiadhesive properties.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9294114      PMCID: PMC508327          DOI: 10.1172/JCI119669

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  56 in total

1.  Identification of an endothelial cell binding site on kininogen domain D3.

Authors:  H Herwald; A A Hasan; J Godovac-Zimmermann; A H Schmaier; W Müller-Esterl
Journal:  J Biol Chem       Date:  1995-06-16       Impact factor: 5.157

2.  Isolation and characterization of the kininogen-binding protein p33 from endothelial cells. Identity with the gC1q receptor.

Authors:  H Herwald; J Dedio; R Kellner; M Loos; W Müller-Esterl
Journal:  J Biol Chem       Date:  1996-05-31       Impact factor: 5.157

3.  Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular "heads" of C1q (gC1q-R).

Authors:  K Joseph; B Ghebrehiwet; E I Peerschke; K B Reid; A P Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

4.  High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation.

Authors:  Y Lin; R B Harris; W Yan; K R McCrae; H Zhang; R W Colman
Journal:  Blood       Date:  1997-07-15       Impact factor: 22.113

5.  Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells.

Authors:  D I Simon; N K Rao; H Xu; Y Wei; O Majdic; E Ronne; L Kobzik; H A Chapman
Journal:  Blood       Date:  1996-10-15       Impact factor: 22.113

6.  Regulation of integrin function by the urokinase receptor.

Authors:  Y Wei; M Lukashev; D I Simon; S C Bodary; S Rosenberg; M V Doyle; H A Chapman
Journal:  Science       Date:  1996-09-13       Impact factor: 47.728

Review 7.  The urokinase receptor and cell migration.

Authors:  F Blasi
Journal:  Semin Thromb Hemost       Date:  1996       Impact factor: 4.180

8.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria.

Authors:  E A Jaffe; R L Nachman; C G Becker; C R Minick
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

9.  Generation of vasoactive peptide bradykinin from human umbilical vein endothelium-bound high molecular weight kininogen by plasma kallikrein.

Authors:  K Nishikawa; Y Shibayama; P Kuna; E Calcaterra; A P Kaplan; S R Reddigari
Journal:  Blood       Date:  1992-10-15       Impact factor: 22.113

10.  Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?

Authors:  G Deng; S A Curriden; S Wang; S Rosenberg; D J Loskutoff
Journal:  J Cell Biol       Date:  1996-09       Impact factor: 10.539

View more
  38 in total

Review 1.  The plasma kallikrein-kinin system counterbalances the renin-angiotensin system.

Authors:  Alvin H Schmaier
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

2.  Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease.

Authors:  Jesús M López-Guisa; Allen C Rassa; Xiaohe Cai; Sarah J Collins; Allison A Eddy
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-26

3.  The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin.

Authors:  Jing-Chuan Zhang; Fernando Donate; Xiaoping Qi; Nicholas P Ziats; Jose C Juarez; Andrew P Mazar; Yuan-Ping Pang; Keith R McCrae
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-26       Impact factor: 11.205

4.  High molecular weight kininogen binds phosphatidylserine and opsonizes urokinase plasminogen activator receptor-mediated efferocytosis.

Authors:  Aizhen Yang; Jihong Dai; Zhanli Xie; Robert W Colman; Qingyu Wu; Raymond B Birge; Yi Wu
Journal:  J Immunol       Date:  2014-03-31       Impact factor: 5.422

5.  Structural basis of interaction between urokinase-type plasminogen activator and its receptor.

Authors:  Cyril Barinka; Graham Parry; Jennifer Callahan; David E Shaw; Alice Kuo; Khalil Bdeir; Douglas B Cines; Andrew Mazar; Jacek Lubkowski
Journal:  J Mol Biol       Date:  2006-08-26       Impact factor: 5.469

6.  Endothelial-cell apoptosis induced by cleaved high-molecular-weight kininogen (HKa) is matrix dependent and requires the generation of reactive oxygen species.

Authors:  Danyu Sun; Keith R McCrae
Journal:  Blood       Date:  2006-01-17       Impact factor: 22.113

Review 7.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

8.  B2 kinin receptor activation is the predominant mechanism by which trypsin mediates endothelium-dependent relaxation in bovine coronary arteries.

Authors:  Grant R Drummond; Stavros Selemidis; Thomas M Cocks
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-05-06       Impact factor: 3.000

9.  A monoclonal antibody to high-molecular weight kininogen is therapeutic in a rodent model of reactive arthritis.

Authors:  Ricardo G Espinola; Audrey Uknis; Irma M Sainz; Irma Isordia-Salas; Robin Pixley; Raul DeLa Cadena; Walter Long; Alexis Agelan; John Gaughan; Albert Adam; Robert W Colman
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

10.  Upregulation of tissue factor in monocytes by cleaved high molecular weight kininogen is dependent on TNF-alpha and IL-1beta.

Authors:  Mohammad M Khan; Yuchuan Liu; Munir E Khan; Megan L Gilman; Sabina T Khan; Michael Bromberg; Robert W Colman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-12-04       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.